SCHEMBL2902147

SCHEMBL2902147

CCOC(=O)C(CC)Oc1cccc(CO)c1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.49
TDP1 Q9NUW8 4/20 0.49
MAPK1 P28482 3/20 0.49
TSHR P16473 3/20 0.49
AR P10275 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.43
PPARG P37231 6/20 0.41
PPARA Q07869 6/20 0.41
LMNA P02545 1/20 0.41
ALDH1A1 P00352 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13433920 0.88 ALDH1A1 (0.45) L3MBTL1TDP1MAPK1TSHRSMN1; SMN2
SCHEMBL14266882 0.87 L3MBTL1 (0.48) L3MBTL1TDP1MAPK1TSHRAR
SCHEMBL13384143 0.87 L3MBTL1 (0.48) L3MBTL1TDP1MAPK1TSHRAR
SCHEMBL2897929 0.87 L3MBTL1 (0.48) L3MBTL1TDP1MAPK1TSHRAR
SCHEMBL13433919 0.85 SMN1; SMN2 (0.56) TSHRSMN1; SMN2PPARGPPARAPTGDR2
SCHEMBL13384140 0.85 L3MBTL1 (0.46) L3MBTL1TDP1MAPK1TSHRAR
SCHEMBL1453864 0.84 L3MBTL1 (0.58) L3MBTL1TDP1MAPK1TSHRSMN1; SMN2
SCHEMBL8450043 0.83 PPARG (0.51) L3MBTL1TDP1TSHRARSMN1; SMN2
SCHEMBL767041 0.81 TDP1 (0.55) L3MBTL1TDP1TSHRARSMN1; SMN2
SCHEMBL1011005 0.78 AR (0.50) L3MBTL1TDP1MAPK1TSHRAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537078-B1 INDOLES HAVING ANTI-DIABETIC ACTIVITY MERCK SHARP & DOHME (US) 2010-04-14 EP disclosed
EP-1537078-B1 INDOLES HAVING ANTI-DIABETIC ACTIVITY MERCK SHARP & DOHME (US) 2010-04-14 EP disclosed
US-7345085-B2 Indoles having anti-diabetic activity MERCK & CO., INC. (US) 2008-03-18 US disclosed
US-7345085-B2 Indoles having anti-diabetic activity MERCK & CO., INC. (US) 2008-03-18 US disclosed
US-7345085-B2 Indoles having anti-diabetic activity MERCK & CO., INC. (US) 2008-03-18 US disclosed
US-20070161689-A1 Indoles having anti-diabetic activity MERCK SHARP & DOHME LLC 2007-07-12 US disclosed
US-20070161689-A1 Indoles having anti-diabetic activity MERCK SHARP & DOHME LLC 2007-07-12 US disclosed
US-20070161689-A1 Indoles having anti-diabetic activity MERCK SHARP & DOHME LLC 2007-07-12 US disclosed
US-7186746-B2 Indoles having anti-diabetic activity MERCK & CO., INC. (US) 2007-03-06 US disclosed
US-7186746-B2 Indoles having anti-diabetic activity MERCK & CO., INC. (US) 2007-03-06 US disclosed
US-7186746-B2 Indoles having anti-diabetic activity MERCK & CO., INC. (US) 2007-03-06 US disclosed
US-20050277685-A1 Indoles having anti-diabetic activity MERCK SHARP & DOHME LLC 2005-12-15 US disclosed
EP-1537078-A1 INDOLES HAVING ANTI-DIABETIC ACTIVITY Merck & Co., Inc. (US) 2005-06-08 EP disclosed
WO-2004020409-A1 INDOLES HAVING ANTI-DIABETIC ACTIVITY MERCK & CO., INC. (US) 2004-03-11 WO disclosed
WO-2004020408-A1 INDOLES HAVING ANTI-DIABETIC ACTIVITY MERCK & CO., INC. (US) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277685-A1 Indoles having anti-diabetic activity GPR119, PPARA, PPARG L3MBTL1 2124/4885TDP1 2563/4885MAPK1 3467/4885
US-20070161689-A1 Indoles having anti-diabetic activity GPR119, PPARA, PPARG L3MBTL1 2124/4885TDP1 2563/4885MAPK1 3467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.